home / stock / idrsf / idrsf quote
Last: | $1.95 |
---|---|
Change Percent: | 0.0% |
Open: | $0 |
Close: | $1.95 |
High: | $0 |
Low: | $0 |
Volume: | 80 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.95 | $0 | $1.95 | $0 | $0 | 80 | 05-02-2024 |
$1.95 | $1.95 | $1.95 | $1.95 | $1.95 | 5,600 | 04-30-2024 |
$2.1 | $2.1 | $2.1 | $2.1 | $2.1 | 315 | 04-29-2024 |
$2.1 | $0 | $2.1 | $0 | $0 | 20 | 04-24-2024 |
$2.1 | $2.1 | $2.1 | $2.1 | $2.1 | 858 | 04-23-2024 |
$2.1 | $1.75 | $2.1 | $2.1 | $1.75 | 2,000 | 04-22-2024 |
$2.03 | $0 | $2.03 | $0 | $0 | 5,000 | 04-15-2024 |
$2.03 | $2.03 | $2.03 | $2.03 | $2.03 | 500 | 04-11-2024 |
$2.65 | $2.65 | $2.65 | $2.65 | $2.65 | 200 | 04-10-2024 |
$2.74 | $2.6 | $2.74 | $2.74 | $2.6 | 12,000 | 04-05-2024 |
$2.75 | $2.75 | $2.75 | $2.75 | $2.75 | 1,506 | 04-04-2024 |
$2.8 | $0 | $2.8 | $0 | $0 | 400 | 04-03-2024 |
$2.8 | $2.8 | $2.8 | $2.8 | $2.8 | 13,100 | 04-02-2024 |
$2.64 | $2.65 | $2.64 | $2.65 | $2.64 | 1,202 | 03-26-2024 |
$2.4 | $2.4 | $2.4 | $2.4 | $2.4 | 3,000 | 03-25-2024 |
$2.48 | $2.4 | $2.48 | $2.48 | $2.36 | 24,689 | 03-22-2024 |
$1.99 | $0 | $1.99 | $0 | $0 | 13 | 03-21-2024 |
$1.99 | $1.99 | $1.99 | $1.99 | $1.99 | 200 | 03-18-2024 |
$1.9 | $1.9 | $1.9 | $1.9 | $1.9 | 282 | 03-06-2024 |
$1.65 | $0 | $1.65 | $0 | $0 | 15 | 03-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Idorsia AG Company Name:
IDRSF Stock Symbol:
OTCMKTS Market:
Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod. Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone pay...
Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, were presented as an oral presentati...
Allschwil, Switzerland – June 2 6 , 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, were presented as ...